One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study - supplementary data

Peter Goadsby
Objective: To assess efficacy and tolerability of 1-year erenumab treatment in patients with episodic migraine. Methods: Patients were randomized (n=955; 1:1:1) during the 24-week double-blind treatment phase (DBTP) to monthly subcutaneous placebo, erenumab 70 or 140mg. At Week 24, 845 patients were re-randomized (1:1) to erenumab 70 or 140mg during the 28-week dose-blinded active-treatment phase (ATP). Monthly migraine days (MMD), achieving ≥50%, ≥75% and 100% reduction in MMD, and safety/tolerability were assessed. Results: Mean MMD...
1 citation reported since publication in 2020.
14 views reported since publication in 2020.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
2 downloads reported since publication in 2020.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?